Integrated Filing — IndAS



General information about company
Scrip Code 500124
NSE Symbol DRREDDY
MSEI Symbol NOTLISTED
ISIN INE089A01031
Name of company Dr. Reddy's Laboratories Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 23-Jul-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-Jun-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 23-Jul-2025   14:15:00
End date and time of board meeting 23-Jul-2025   15:43:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 85721000000
Other income 2903000000
Total income 88624000000
2 Expenses
(a) Cost of materials consumed 20358000000
(b) Purchases of stock-in-trade 12159000000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -4442000000
(d) Employee benefit expense 15035000000
(e) Finance costs 830000000
(f) Depreciation, depletion and amortisation expense 4761000000
(f) Other Expenses
1 Other expenses 20875000000 20875000000
Total other expenses 20875000000
Total expenses 69576000000
3 Total profit before exceptional items and tax 19048000000
4 Exceptional items 0
5 Total profit before tax 19048000000
6 Tax expense
7 Current tax 10261000000
8 Deferred tax -5310000000
9 Total tax expenses 4951000000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 14097000000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 2000000
16 Total profit (loss) for period 14099000000
17 Other comprehensive income net of taxes 2049000000
18 Total Comprehensive Income for the period 16148000000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 14181000000
Total profit or loss, attributable to non-controlling interests -82000000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 16230000000
Total comprehensive income for the period attributable to owners of parent non-controlling interests -82000000
21 Details of equity share capital
Paid-up equity share capital 835000000
Face value of equity share capital 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 17.04
Diluted earnings (loss) per share from continuing operations 17.02
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 17.04
Diluted earnings (loss) per share from continuing and discontinued operations 17.02
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) As per the results attached



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Global Generics 75732000000 75732000000
2 Pharmaceutical Services and Active Ingredients 9874000000 9874000000
3 Others 1643000000 1643000000
Total Segment Revenue 87249000000
Less: Inter segment revenue 1528000000 1528000000
Revenue from operations 85721000000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Global Generics 46086000000 46086000000
2 Pharmaceutical Services and Active Ingredients 1087000000 1087000000
3 Others 1459000000 1459000000
Total Profit before tax 48632000000
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income 29582000000 29582000000
Profit before tax 19050000000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Global Generics 0 0
2 Pharmaceutical Services and Active Ingredients 0 0
3 Others 0 0
Total Segment Asset 0 0
Un-allocable Assets 0 0
Net Segment Asset 0 0
4 Segment Liabilities
Segment Liabilities
1 Global Generics 0 0
2 Pharmaceutical Services and Active Ingredients 0 0
3 Others 0 0
Total Segment Liabilities 0 0
Un-allocable Liabilities 0 0
Net Segment Liabilities 0 0
Disclosure of notes on segments Textual Information(2)



Text Block
Textual Information(2) As per the results attached



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified subsequently to profit or loss 5000000 5000000
Total Amount of items that will not be reclassified to profit and loss 5000000
2 Income tax relating to items that will not be reclassified to profit or loss 0
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified subsequently to profit or loss 2077000000 2077000000
Total Amount of items that will be reclassified to profit and loss 2077000000
4 Income tax relating to items that will be reclassified to profit or loss 33000000
5 Total Other comprehensive income 2049000000